Finland

Citryll secures €85M Series B Funding to advance NET-Targeting Therapy for Inflammatory Diseases
Oss-based Citryll, a biotech company pioneering therapies for immune-mediated inflammatory diseases, has closed an €85 million Series B funding round.
Helsinki-based Valpas, a tech company specializing in pesticide-free solutions to keep hotels bedbug-safe, has announced a successful €4 million seed funding round. The investment was led by Zenith VC, with participation from Icebreaker VC, Finnish Industry Investment, Canon Marketing Japan MIRAI Fund, Activum SG Ventures, Houghton Street Ventures, Rockaway Ventures,